

Eberhard Standl

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6543241/eberhard-standl-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

8,620
citations

26
h-index

71
g-index

71
ext. papers

9,993
ext. citations

10.9
avg, IF

5.54
L-index

#	Paper	IF	Citations
60	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet, The</i> , 2005 , 366, 1279-89	40	3186
59	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015 , 373, 232-42	59.2	1739
58	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2007 , 28, 88-136	9.5	889
57	The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. <i>European Heart Journal</i> , 2004 , 25, 1880-90	9.5	394
56	Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. <i>European Heart Journal</i> , 2007 , 28, 1402-1402	9.5	329
55	Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). <i>Diabetes Care</i> , 2007 , 30, 2773-8	14.6	212
54	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 877-886	18.1	164
53	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 126-35	16.2	161
52	Therapeutic potential of αglucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1959-81	4	142
51	Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 25-32	3.9	133
50	Postprandial hyperglycemia and glycemic variability: should we care?. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S120-7	14.6	127
49	Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. <i>Diabetes and Vascular Disease Research</i> , 2012 , 9, 163-9	3.3	94
48	Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. <i>European Heart Journal</i> , 2008 , 29, 177-84	9.5	79
47	The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. <i>Diabetes Technology and Therapeutics</i> , 2004 , 6, 579-88	8.1	72
46	The global epidemics of diabetes in the 21st century: Current situation and perspectives. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 7-14	3.9	68
45	Current perspectives on cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , 2016 , 15, 139	8.7	51
44	Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. <i>Diabetes Care</i> , 2020 , 43, 1427-1432	14.6	47

43	Defending the con side: obesity paradox does not exist. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S282-6	14.6	47
42	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017 , 40, 1763-1770	14.6	46
41	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016 , 118, 1830-43	15.7	46
40	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018 , 41, 596-603	14.6	44
39	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 391-402	18.1	42
38	Updates on cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , 2017 , 16, 128	8.7	36
37	Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014 , 16, 353	2.1	34
36	On the potential of acarbose to reduce cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2014 , 13, 81	8.7	34
35	Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. <i>Diabetes Care</i> , 2005 , 28, 419-20	14.6	33
34	Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. <i>Circulation: Heart Failure</i> , 2013 , 6, 203-10	7.6	24
33	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019 , 40, 2907-2919	9.5	22
32	New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S172-9	14.6	19
31	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. <i>BMJ Open</i> , 2012 , 2,	3	19
30	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020 , 43, 643-652	14.6	19
29	DPP-4 inhibitors and risk of heart failure EXAMINED. <i>Lancet, The</i> , 2015 , 385, 2022-4	4.0	17
28	The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. <i>Journal of Diabetes and Its Complications</i> , 2011 , 25, 202-7	3.2	12
27	The impact of glucose-lowering therapy on cardiovascular outcomes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009 , 23, 401-11	6.5	11
26	On the prognostic value of post-load glucose in patients with coronary artery disease. <i>European Heart Journal</i> , 2018 , 39, 2746-2748	9.5	10

25	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , 2017 , 70, 907-914	8.5	10
24	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 2026-2034	12.3	9
23	Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>Stroke</i> , 2013 , 44, 2590-3	6.7	8
22	Dysglycemia and abdominal obesity. <i>Current Vascular Pharmacology</i> , 2012 , 10, 678-9	3.3	8
21	GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 741-743	18.1	7
20	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. <i>Diabetes Research and Clinical Practice</i> , 2020 , 161, 108054	7.4	7
19	What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons. <i>Diabetes/Metabolism Research and Reviews</i> , 2012 , 28 Suppl 2, 60-6	7.5	7
18	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , 2021 , 20, 218	8.7	7
17	Corrections needed to 2016 ESC and AHA guidelines on heart failure. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 325-326	18.1	6
16	Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?. <i>Diabetes Care</i> , 2008 , 31 Suppl 2, S136-9	14.6	6
15	Targets for blood glucose: What have the trials told us. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 64-72	3.9	6
14	Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 99-114	3.3	5
13	Hypoglycaemia and its management in primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3332	7.5	4
12	Metformin in type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 567-569	18.1	4
11	Heart failure outcomes and Covid-19. <i>Diabetes Research and Clinical Practice</i> , 2021 , 175, 108794	7.4	4
10	Glycemic control: a combination of lifestyle management and the use of drugs. <i>Cardiology and Therapy</i> , 2013 , 2, 1-16	2.8	3
9	New Aspects in Diabetes 1992 ,		3
8	Diabetologie in Klinik und Praxis 2003 ,		3

7	Clinical features and treatment of coronary heart disease in diabetes 2015 , 1064-1078		1
6	Diabetes and cardiovascular disease. <i>Clinical Research in Cardiology Supplements</i> , 2010 , 5, 27-34	3.1	1
5	Heart failure in diabetes: From an increased risk to a treatment target. <i>Diabetes Mellitus</i> , 2018 , 21, 399-408		1
4	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , 2021 , 177, 108870	7.4	1
3	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 50	8.7	1
2	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. <i>Diabetes Care</i> 2019;42:157-163. <i>Diabetes Care</i> , 2019 , 42, e95	14.6	
1	Guideline Development for Medical Device Technology: Issues for Consideration.. <i>Journal of Diabetes Science and Technology</i> , 2022 , 19322968221093355	4.1	